April 24, 2017

Registration  13:30 – 18:30

CONFERENCE OPENING CEREMONY  14:00 – 14:30

Conference opening
   Michael R. Shurin (Chair, CITIM Organizing Committee)
Greetings
   Mr. Oldřich Lomecký, Mayor of Prague
   Czech Immunological Society, Blanka Rihova (Prague, Czech Rep)
   Association for Cancer Immunotherapy/European Network Cancer Immunotherapy
   (CIMT/ENCI), Christoph Huber (Mainz, Germany)
   Cancer Microenvironment Society (ICMS), Isaac Witz (Tel Aviv, Israel)
   PIVAC, Graham Pawelec (Tübingen, Germany)
   Israeli Society for Cancer Research, Angel Porgador (Beer Sheva, Israel)
Welcome remarks and Information
   Luca Vannucci (Chair, Local Organizing Committee)
   Viktor Umansky (CITIM Organizing Committee)

KEYNOTE LECTURE  14:30 – 15:30
(Sponsored by Immudex)
   Chair: Viktor Umansky (Heidelberg, Germany)

Giorgio Trinchieri
   NIH Distinguished Investigator
   Director, Cancer and Inflammation Program
   Center for Cancer Research, NCI, NIH
   Associate Director for Basic Science
   Trans-NIH Center for human Immunology
   Bethesda, Maryland, USA

Cancer as a disease of the symbiont/metaorganism

PLENARY SESSION 1  15:40 – 17:40
Immunity and the malignant process I
   Chair: Dmitry Gabrilovich (Philadelphia, PA, USA)
   Chair: Blanka Říhová (Prague, Czech Rep)

Isaac Witz (Tel Aviv, Israel)  15:40 - 16:10
   The metastatic microenvironment: Tumor-associated and microenvironmental drivers of metastasis

Sven Brandau (Essen, Germany)  16:10 - 16:40
   Novel functions of toll-like receptors in tumor immunity
**Suzanne Ostrand-Rosenberg** (Baltimore, MD, USA) 16:40 - 17:10
High fat diet and leptin drive myeloid-derived suppressor cells (MDSC) that protect against metabolic dysfunction, but promote tumor progression

**Paul Lehmann** (Cleveland, OH, USA) 17:10 - 17:40
The natural history of autoreactive (tumor reactive?) T cells

Coffee break 17:40 – 18:00

**PLENARY SESSION 2**
**Immunity and the malignant process II** 18:00 – 19:35
Chair: Michal Baniyash (Jerusalem, Israel)
Chair: Janko Kos (Ljubljana, Slovenia)

**Christoph Huber** (Mainz, Germany) 18:00 – 18:30
Exploiting the mutanome for tumor vaccination

**Elena Voronov** (Beer Sheva, Israel) 18:30 – 18:55
A dual effect of IL-1 alpha in colon inflammation and inflammation-related colon cancer

**Dmitriy W. Gutkin** (Pittsburgh, PA, USA) 18:55 – 19:15
Immune infiltrate in premalignant lesions

**Natalia Aptsiauri** (Granada, Spain) 19:15 – 19:35
Correlation between HLA class I and PD-L1/PD1 expression in human tumors

Welcome reception, Hotel Ambassador 19:45 – 22:00
April 25, 2017

**Keynote Presentation**  
8:20 – 9:05  
Chair: Arthur Hurwitz (Lexington, MA, USA)

**Rolf Kiessling** (Stockholm, Sweden)  
*Counteracting tumor induced immune suppression*

**PLENARY SESSION 3**  
9:05 – 10:55  
**Regulatory pathways in the tumor immunoenvironment I**

Chair: Viktor Umansky (Heidelberg, Germany)  
Chair: Joost J. Oppenheim (Frederick, MD, USA)

**Federico Garrido** (Granada, Spain)  
*Rejection versus escape: The tumour MHC dilemma*  
9:05 - 9:35

**Dmitry I. Gabrilovich** (Philadelphia, PA, USA)  
*Regulation of myeloid cell differentiation in cancer*  
9:35 - 10:05

**Yuri Bunimovich** (Pittsburgh, PA, USA)  
*Neuroglial support of the melanoma microenvironment*  
10:05 - 10:25

**Michael R. Shurin** (Pittsburgh, PA, USA)  
*Cancer-PNS-Immune axis: New concept and new data*  
10:25 - 10:50

Coffee break  
10:50 – 11:15

**PLENARY SESSION 4**  
11:15 – 13:25  
**Regulatory pathways in the tumor immunoenvironment II**

Chair: Isaac Witz (Tel Aviv, Israel)  
Chair: Lenka Zdrazilová-Dubská (Brno, Czech Rep)

**Zvi G. Fridlender** (Jerusalem, Israel)  
*New mechanisms by which tumor related neutrophil sub-populations affect tumor growth*  
11:15 - 11:40

**Viktor Umansky** (Heidelberg, Germany)  
*Immunoregulatory circuits in melanoma microenvironment*  
11:40 - 12:05

**Adit Ben-Baruch** (Tel Aviv, Israel)  
*Inflammation-driven tumor-stroma interactions in breast cancer*  
12:05 - 12:35

**Jonathan Weiss** (Frederick, MD, USA)  
*Crosstalk between macrophage metabolism and tumor progression*  
12:35 - 12:55

**Blanka Říhová** (Prague, Czech Rep)  
*Polymeric prodrugs act as endogeneous vaccines*  
12:55 - 13:25

Lunch break  
13:25 – 14:20
PLENARY SESSION 5   14:20 – 16:40
Regulatory pathways in the tumor immunoenvironment III

Chair: Suzanne Ostrand-Rosenberg (Baltimore, MD, USA)
Chair: Graham Pawelec (Tübingen, Germany)

Michal Baniyash (Jerusalem, Israel)   14:20 - 14:50
The plasticity of myeloid-derived suppressor cells: Clinical implications

Nathan Karin (Haifa, Israel)   14:50 – 15:20
CCR5 directs the mobilization of Gr1+CD11b+Ly6Clow polymorphonuclear myeloid cells from the bone marrow to the blood and their colonization at the tumor site

Salem Chouaib (Villejuif, France)   15:20 - 15:50
Regulation of immune resistance and immune suppression by hypoxia

Lenka Zdrazilova-Dubska (Brno, Czech Rep)   15:50 - 16:10
Immunomonitoring of patients treated by cancer immunotherapy: rationale and showcases

Udo Gaipl (Erlangen, Germany)   16:10 - 16:40
Immune modulatory properties of radiotherapy - rationales for combination with immunotherapy

Coffee break   16:40 – 17:20

POSTER SESSION   16:40 – 17:55

Prague overview sightseeing walking tour for CITIM-2017 participants   18:00 – 20:00
Keynote Presentation

Graham Pawelec (Tübingen, Germany)

Immune signatures predicting responses to immunomodulatory antibody therapy

PLENARY SESSION 6

Inflammation, microbiota and cancer: regulatory mechanisms

Chair: Jay A. Berzofsky (Bethesda, MD, USA)
Chair: Catherine Sautes-Fridman (Paris, France)

Ron Apte (Beer-Sheva, Israel) 9:20 – 9:45

The microenvironment shifts the balance between inflammation and immunity in tumors

Janko Kos (Ljubljana, Slovenia) 9:45 – 10:05

Cystatin F dependent regulation of NK and T cell cytotoxicity

Miloslav Kverka (Prague, Czech Rep) 10:05 – 10:25

Diet and microbiota as modulators of gut inflammation and colon cancer

Anahid Jewett (Los Angeles, CA, USA) 10:25 – 10:50

Systemic regulation of super-charged NK cell function by intestinal microflora in BLT humanized mice leads to lysis, growth inhibition and balanced differentiation of Cancer Stem Cells

Luca Vannucci (Prague, Czech Rep) 10:50 – 11:15

Stroma and immunity cross-talk builds the tumor microenvironment

Mathias Chamaillard (Lille, France) 11:15 – 11:35

Remote control of intestinal tumorigenesis by the gut microbiota

Coffee break 11:35 – 11:50

PLENARY SESSION 7

Cancer immunotherapy I: New concepts and clinical data

Chair: Esteban Celis (Augusta, GA, USA)
Chair: Eitan Yefenof (Jerusalem, Israel)

Jay A. Berzofsky (Bethesda, MD, USA) 11:50 – 12:20

Cancer Vaccine Strategies: Translation from mice to human clinical trials

Wolf H. Fridman (Paris, France) 12:20 – 12:50

Integration of molecular and immune classifications in human cancers: a guide for immunotherapies

Gurkamal S. Chatta (Buffalo, NY, USA) 12:50 – 13:15

Chemokine modulation in Genito-urinary malignancies

Yulia Nefedova (Philadelphia, PA, USA) 13:15 – 13:35

Regulation of tumor cell survival by myeloid cells in the bone marrow microenvironment
William J. Murphy (Sacramento, CA, USA) 13:35 – 14:00
Impact of obesity on T cell exhaustion and effects on immunotherapy

Lunch break 14:00 – 14:50

PLENARY SESSION 8 14:50 – 16:40
Cancer immunotherapy II: New targets and models

Yasmin Thanavala (Buffalo, NY, USA) 14:50 – 15:10
Immunosuppressive pathways in HCC patients and beneficial immunomodulation following sorafenib therapy

Esteban Celis (Augusta, GA, USA) 15:10 – 15:35
Peptide vaccines for cancer can be effective, when used properly

Dmitri Loukinov (Rockville, MD, USA) 15:35 – 15:55
BORIS molecule is an attractive target for efficient immunotherapy of cancer

Arthur Hurwitz (Lexington, MA, USA) 15:55 – 16:20
Enhancing T cell responses to promote more durable tumor immunity

Benjamin Sredni (Ramat-Gan, Israel) 16:20 – 16:40
Redox modulation of adjacent thiols in VLA-4 by the immunomodulatory AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state

Coffee break 16:40 – 17:00

PLENARY SESSION 9  Selected presentations 17:00 – 17:50

Tali Feferman (Rechovot, Israel)
Hypoxia restricts CTL-mediated tumor rejection: insights from live intratumoral imaging

Cecile Gouttefangeas (Tübingen, Germany)
A new -toll like receptor ligand as strong adjuvant for peptide vaccination

Paulo Rodrigues-Santos (Coimbra, Portugal)
Tyrosine kinase inhibitors modulate the expression of PD-1 receptor on regulatory T cells in chronic myeloid leukemia

Flavio Salazar Onfray (Santiago, Chile)
A new vaccine based on Conditioned Melanoma Lysates (TRIMELVax™) induces anti-tumor immune responses inhibiting tumor growth

Stephen Haley (Fairfax, VA, USA)
Why take a chance you are missing something? MHC Dextramers for the detection of tumor-specific T cells
Volume 10 (2021) – 18:00 – 19:50

Cancer immunotherapy III: Novel approaches and perspectives

Chair: Angel Porgador (Beer Sheva, Israel)
Chair: Marek Kovář (Prague, Czech Rep)

Jiřina Bartůňková (Prague, Czech Rep) 18:00 – 18:20
Cell-based immunotherapy for solid tumors

Lea Eisenbach (Rehovot, Israel) 18:20 – 18:50
Anti-tumor vaccines: simple, sophisticated, combined

Catherine Sautes-Fridman (Paris, France) 18:50 – 19:20
Immune-based identification of patients with high risk of progression in clear cell Renal Cell Carcinoma

Thomas Sayers (Frederick, MD, USA) 19:20 – 19:50
Sensitization of melanoma cells to caspase-8-dependent cell death by specific 17beta-hydroxywithanolides
April 27, 2017

Keynote Presentation 8:30 – 9:15

Chair: Luca Vannucci (Prague, Czech Rep)

Robert Ferris (Pittsburgh, PA, USA)
Novel immunotherapeutic strategies and combinations to overcome immune escape in head and neck cancer

PLENARY SESSION 11 9:20 – 11:30
Cancer immunotherapy IV: Novel applications and mechanisms

Chair: Federico Garrido (Granada, Spain)
Chair: Qing Yi (Cleveland, OH, USA)

Joost J. Oppenheim (Frederick, MD) 9:20 – 9:50
Curative immunotherapeutic strategy for the treatment of big CT26 and other tumors in mice

Per thor Straten (Herlev, Denmark) 9:50 – 10:20
Cancer therapy using T cells and running shoes

Sjoerd H. Van der Burg (Leiden, The Netherlands) 10:20 – 10:50
Combination of non-immunogenic cell death inducing chemotherapy and immunotherapy for improved tumor immunity

Shimon Slavin (Tel Aviv, Israel) 10:50 – 11:10
Innovative immunotherapy for prevention and treatment of relapse following conventional chemotherapy or stem cell transplantation

Sebastian Bunk (Tübingen, Germany) 11:10 – 11:30
Discovery and validation of TCRs for immunotherapeutic application

Coffee break 11:30 – 11:50

PLENARY SESSION 12 11:50 – 14:10
Cancer immunotherapy V: New approaches and rationales

Chair: Ron Apte (Beer Sheva, Israel)
Chair: Paul Lehmann (Cleveland, OH, USA)

Eitan Yefenof (Jerusalem, Israel) 11:50 – 12:20
MicroRNAs as diagnostic and therapeutic tools in leukemia

Yona Keisari (Tel Aviv, Israel) 12:20 – 12:50
Development of an Integrated Novel Radiotherapy and Immunotherapy cancer treatment: The journey from the pre-clinical to clinical trials

Marek Kovář (Prague, Czech Rep) 12:50 – 13:10
Complexes of IL-2 and anti-IL-2 mAb in cancer immunotherapy

Fabrizio Mattei (Rome, Italy) 13:10 – 13:40
Microfluidic technology as a new tool to investigate cancer and immune cells crosstalk for immunotherapy
Lunch break 13:40 – 14:30

PLENARY SESSION 13  Best Abstract presentations  14:30 – 15:20

Chair: Mads Andersen (Herlev, Denmark)
Chair: Anahid Jewett (Los Angeles, CA, USA)

Qing Ma (Houston, TX, USA)
LFA-1 activation in leukemia immunotherapy

Valeria Lucarini (Rome, Italy)
IL-33 inhibits melanoma growth and pulmonary metastasis in mice through recruitment and activation of eosinophils

Adrianna Grzelak (Prague, Czech Republic)
Combined immunotherapy of tumors with downregulated expression of MHC class I molecules

Nicolai Grønne Jørgensen (Harlev, Denmark)
Peptide vaccination against PD-L1 in multiple myeloma

Tillmann Michels (Regensburg, Germany)
Olfactory receptor signaling as a novel immune checkpoint in solid tumors

Coffee break 15:20 – 15:40

PLENARY SESSION 14  15:40 – 17:50
Cancer immunotherapy VI: New approaches and rationales

Chair: Rolf Kiessling (Stockholm, Sweden)
Chair: William Murphy (Sacramento, CA, USA)

Angel Porgador (Beer Sheva, Israel)  15:40 – 16:10
Natural Killer Immunity and Cancer Immunome

Georgi Guruli (Richmond, VA, USA)  16:10 – 16:30
Monitoring dendritic cells trafficking in mice using Multi-Spectral Imaging

Mansour Haeryfar (London, Ontario, Canada)  16:30 – 16:50
MAIT Cells in Colorectal Carcinoma: Friend or Foe?

Qing Yi (Cleveland, OH, USA)  16:50 – 17:20
New T cell subsets for cancer adoptive cell therapy

Mads Andersen (Herlev, Denmark)  17:20 – 17:50
Anti-regulatory T cells: An alternative approach to target immunosuppressive mechanisms

CONFERENCE CLOSING: CONCLUDING REMARKS  17:50 – 18:20

Natalia Aptsiauri – Introduction to CITIM-2019

Banquet 19:45